Back to Search
Start Over
Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit SEL-212 Designed to be First Non-Immunogenic Uricase Therapeutic for Severe Gout Data Show Substantial and Sustained Reduction of Serum Uric Acid Levels for 30 Days or Longer After Single Dose Company to Host Conference Call Tomorrow Morning
Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit SEL-212 Designed to be First Non-Immunogenic Uricase Therapeutic for Severe Gout Data Show Substantial and Sustained Reduction of Serum Uric Acid Levels for 30 Days or Longer After Single Dose Company to Host Conference Call Tomorrow Morning
- Source :
- Plus Company Updates. December 28, 2016
- Publication Year :
- 2016
-
Abstract
- Watertown: Selecta Biosciences, Inc. has issued the following press release: Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.475460777